🏅 FDA Orphan Designation

Spevigo

spesolimab-sbzo

Manufacturer: Boehringer Ingelheim Pharmaceuticals, Inc. (BI)

Indicated for:

FDA-Approved Indications (1)

Generalized pustular psoriasisOrphan Designation

treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients 12 years of age and older and weighing at least 40 kg

Indications & Usage

1 INDICATIONS AND USAGE SPEVIGO is indicated for the treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients 12 years of age and older and weighing at least 40 kg. SPEVIGO is an interleukin-36 receptor antagonist indicated for the treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients 12 years of age and older and weighing at least 40 kg. ( 1 )

💙 Support Programs

View all →

SPEVIGO

Boehringer Ingelheim

Copay card ↗Apply ↗

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.